NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Neurotrope, Inc. (NASDAQ:NTRP) securities between January 7, 2016 and April 28, 2017 (the “Class Period”). Investors have until July 17, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the efficacy of Bryostatin, a drug that Neurotrope was developing to treat Alzheimer’s.
On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin. However, the trial data contradicted Neurotrope’s statements, and the top-line data relating to the 20 microgram dose of Bryostatin failed to produce results that were statistically significant. Following this news, shares of Neurotrope fell $11.84, or over 63%, to close at $6.97 per share on May 1, 2017.
If you purchased or otherwise acquired Neurotrope securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Neurotrope lawsuit, please go to http://www.bespc.com/ntrp. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.